Send me real-time posts from this site at my email
Motley Fool

Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday

What happened

On Tuesday, shares of up-and-coming biotechs Marinus Pharmaceuticals (NASDAQ: MRNS), iBio (NYSEMKT: IBIO), and Arcturus Therapeutics Holdings (NASDAQ: ARCT) fell by 12%, 13%, and 19%, respectively.

One common catalyst seems to be the secondary-share issues announced by all three companies, although another important factor may be at play.

Image source: Getty Images.

So what

iBio and Marinus are making fairly sizable issues given their current market capitalizations. The former is seeking to raise gross proceeds of $35 million; its latest market-cap figure is nearly $239 million. Marinus would like to reap $70 million; it is currently valued at $421 million by investors. That means some notable share dilution for both biotechs.

Arcturus is a bit more of a mystery. It's seeking to raise "only" $150 million in its flotation, against a market cap approaching $2.5 billion.

But in the case of Arcturus and iBio, the share-dilution issue might be compounded by the perception that both are falling behind in the coronavirus vaccine race. Both have candidates that are in development but have not yet advanced as far as rivals in clinical testing.

Now what

While share dilution is a real concern, these companies still have good potential, so a "buy on weakness" should be seriously considered for all three. Marinus' ganaxolone pipeline epilepsy drug has tested well, and iBio and Marinus remain intriguing underdog coronavirus vaccine plays.

10 stocks we like better than Arcturus Therapeutics Holdings Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Arcturus Therapeutics Holdings Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 20, 2020

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue